349 related articles for article (PubMed ID: 21050066)
1. Optimization of a Yellow fluorescent protein-based iodide influx high-throughput screening assay for cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
Sui J; Cotard S; Andersen J; Zhu P; Staunton J; Lee M; Lin S
Assay Drug Dev Technol; 2010 Dec; 8(6):656-68. PubMed ID: 21050066
[TBL] [Abstract][Full Text] [Related]
2. Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
Lin S; Sui J; Cotard S; Fung B; Andersen J; Zhu P; El Messadi N; Lehar J; Lee M; Staunton J
Assay Drug Dev Technol; 2010 Dec; 8(6):669-84. PubMed ID: 21050065
[TBL] [Abstract][Full Text] [Related]
3. A Homogeneous Cell-Based Halide-Sensitive Yellow Fluorescence Protein Assay to Identify Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Ion Channel.
Smith E; Giuliano KA; Shumate J; Baillargeon P; McEwan B; Cullen MD; Miller JP; Drew L; Scampavia L; Spicer TP
Assay Drug Dev Technol; 2017 Dec; 15(8):395-406. PubMed ID: 29172645
[TBL] [Abstract][Full Text] [Related]
4. High-throughput screening of libraries of compounds to identify CFTR modulators.
Pedemonte N; Zegarra-Moran O; Galietta LJ
Methods Mol Biol; 2011; 741():13-21. PubMed ID: 21594775
[TBL] [Abstract][Full Text] [Related]
5. Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Chung WJ; Goeckeler-Fried JL; Havasi V; Chiang A; Rowe SM; Plyler ZE; Hong JS; Mazur M; Piazza GA; Keeton AB; White EL; Rasmussen L; Weissman AM; Denny RA; Brodsky JL; Sorscher EJ
PLoS One; 2016; 11(10):e0163615. PubMed ID: 27732613
[TBL] [Abstract][Full Text] [Related]
6. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
Birault V; Solari R; Hanrahan J; Thomas DY
Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
[TBL] [Abstract][Full Text] [Related]
7. Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms.
Roxo-Rosa M; Xu Z; Schmidt A; Neto M; Cai Z; Soares CM; Sheppard DN; Amaral MD
Proc Natl Acad Sci U S A; 2006 Nov; 103(47):17891-6. PubMed ID: 17098864
[TBL] [Abstract][Full Text] [Related]
8. Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease.
Pasyk S; Li C; Ramjeesingh M; Bear CE
Biochem J; 2009 Feb; 418(1):185-90. PubMed ID: 18945216
[TBL] [Abstract][Full Text] [Related]
9. Identification of natural coumarin compounds that rescue defective DeltaF508-CFTR chloride channel gating.
Xu LN; Na WL; Liu X; Hou SG; Lin S; Yang H; Ma TH
Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):878-83. PubMed ID: 18430055
[TBL] [Abstract][Full Text] [Related]
10. A new 9-alkyladenine-cyclic methylglyoxal diadduct activates wt- and F508del-cystic fibrosis transmembrane conductance regulator (CFTR) in vitro and in vivo.
Boucherle B; Bertrand J; Maurin B; Renard BL; Fortuné A; Tremblier B; Becq F; Norez C; Décout JL
Eur J Med Chem; 2014 Aug; 83():455-65. PubMed ID: 24992073
[TBL] [Abstract][Full Text] [Related]
11. Simple image-based no-wash method for quantitative detection of surface expressed CFTR.
Larsen MB; Hu J; Frizzell RA; Watkins SC
Methods; 2016 Mar; 96():40-45. PubMed ID: 26361332
[TBL] [Abstract][Full Text] [Related]
12. Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
Cai ZW; Liu J; Li HY; Sheppard DN
Acta Pharmacol Sin; 2011 Jun; 32(6):693-701. PubMed ID: 21642944
[TBL] [Abstract][Full Text] [Related]
13. Transient receptor potential canonical channel 6 links Ca2+ mishandling to cystic fibrosis transmembrane conductance regulator channel dysfunction in cystic fibrosis.
Antigny F; Norez C; Dannhoffer L; Bertrand J; Raveau D; Corbi P; Jayle C; Becq F; Vandebrouck C
Am J Respir Cell Mol Biol; 2011 Jan; 44(1):83-90. PubMed ID: 20203293
[TBL] [Abstract][Full Text] [Related]
14. CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis.
Verkman AS; Lukacs GL; Galietta LJ
Curr Pharm Des; 2006; 12(18):2235-47. PubMed ID: 16787252
[TBL] [Abstract][Full Text] [Related]
15. HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR.
Moniz S; Sousa M; Moraes BJ; Mendes AI; Palma M; Barreto C; Fragata JI; Amaral MD; Matos P
ACS Chem Biol; 2013 Feb; 8(2):432-42. PubMed ID: 23148778
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening.
Pedemonte N; Lukacs GL; Du K; Caci E; Zegarra-Moran O; Galietta LJ; Verkman AS
J Clin Invest; 2005 Sep; 115(9):2564-71. PubMed ID: 16127463
[TBL] [Abstract][Full Text] [Related]
17. High-throughput screening identifies FAU protein as a regulator of mutant cystic fibrosis transmembrane conductance regulator channel.
Tomati V; Pesce E; Caci E; Sondo E; Scudieri P; Marini M; Amato F; Castaldo G; Ravazzolo R; Galietta LJV; Pedemonte N
J Biol Chem; 2018 Jan; 293(4):1203-1217. PubMed ID: 29158263
[TBL] [Abstract][Full Text] [Related]
18. Impact of the cystic fibrosis mutation F508del-CFTR on renal cyst formation and growth.
Li H; Yang W; Mendes F; Amaral MD; Sheppard DN
Am J Physiol Renal Physiol; 2012 Oct; 303(8):F1176-86. PubMed ID: 22874761
[TBL] [Abstract][Full Text] [Related]
19. The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylation.
Pasyk S; Molinski S; Ahmadi S; Ramjeesingh M; Huan LJ; Chin S; Du K; Yeger H; Taylor P; Moran MF; Bear CE
Proteomics; 2015 Jan; 15(2-3):447-61. PubMed ID: 25330774
[TBL] [Abstract][Full Text] [Related]
20. Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy.
Bangel-Ruland N; Tomczak K; Fernández Fernández E; Leier G; Leciejewski B; Rudolph C; Rosenecker J; Weber WM
J Gene Med; 2013; 15(11-12):414-26. PubMed ID: 24123772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
